The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite a remarkably low P/E of 0.48 suggesting deep value, this is likely due to negative earnings or accounting distortions, as evidenced by the negative Price/Book ratio of -4.06, which signals shareholder equity deficiency. Revenue and earnings are contracting sharply year-over-year, with earnings down 50%, while operating cash flow and balance sheet metrics are unavailable, raising transparency concerns. Analysts recommend a 'buy' with a $29.73 target, implying 41% upside, but this contrasts with deteriorating fundamentals and bearish technicals.